奥美沙坦酯与氨氯地平联合氢氯噻嗪治疗高血压的临床研究

目的 探讨奥美沙坦酯与氨氯地平联合氢氯噻嗪治疗高血压的疗效对比。方法 选取2017年2月—2019年2月新疆喀什地区第二人民医院治疗的100例高血压患者为研究对象，根据随机数字表法将患者分为对照组和观察组，每组各50例。对照组患者口服苯磺酸氨氯地平片，5 mg/次，1次/d；氢氯噻嗪片，25 mg/次，1次/d。观察组患者口服奥美沙坦酯片，20 mg/次，1次/d。氢氯噻嗪片用法同对照组。两组均连续治疗2个月。观察两组患者的临床疗效，同时比较两组患者治疗前后的24 h动态血压情况和血清因子水平。结果 治疗后，观察组患者的降压总有效率为92.00%，显著高于对照组的74.00%（P<0.05）。治疗后，两组患者24 h动态血压均明显降低（P<0.05），且观察组显著低于对照组（P<0.05）。治疗后，两组患者同型半胱氨酸（Hcy）、超敏C反应蛋白（hs-CRP）水平均明显降低（P<0.05），且观察组各血清因子水平均显著低于对照组（P<0.05）。结论 奥美沙坦酯联合氢氯噻嗪可有效控制血压水平，降低血清因子水平，对促进高血压患者病情康复具有积极意义。

Clinical study of olmesartan medoxomil and amlodipine combined with hydrochlorothiazide in treatment of hypertension

Objective To compare the efficacy of olmesartan medoxomil and amlodipine combined with hydrochlorothiazide in treatment of hypertension. Methods A total of 100 patients with hypertension in the Kashgar Second People''s Hospital, Xinjiang from February 2017 to February 2019 were selected as the research objects. According to the random number table method, the patients were divided into the control group and the observation group, with 50 patients in each group. Patients in the control group were po administered with Amlodipine Besylate Tablets, 5 mg/time, once daily, and Hydrochlorothiazide Tablets, 25 mg/time, once daily. Patients in the observation group were po administered with Olmesartan Medoxomil Tablets, 20 mg/time, once daily, and Hydrochlorothiazide Tablets were used as the control group. Both groups were treated continuously for 2 months. The clinical efficacy of two groups was observed, and the 24 h dynamic blood pressure and serum factor levels before and after treatment in two groups were compared. Results After treatment, the total effective rate of hypotension in the observation group was 92.00%, which was significantly higher than 74.00% in the control group (P<0.05). After treatment, the 24 h dynamic blood pressure in two groups was significantly decreased (P<0.05), and 24 h dynamic blood pressure in the observation group was significantly lower than those in the control group (P<0.05). After treatment, the levels of Hcy and hs-CRP in two groups were significantly decreased (P<0.05), and the levels of serum factors in the observation group were significantly lower than those in the control group (P<0.05). Conclusion Olmesartan medoxomil combined with hydrochlorothiazide can effectively control the blood pressure level and reduce the serum factor level, which is of positive significance for promoting the rehabilitation of hypertension patients.